Connected injectable medicine collaboration formed between Haselmeier and Common Sensing

Swiss-based developer and manufacturer of innovative self-injection devices, Haselmeier, and a Cambridge-based smart injector monitoring and support solutions company, Common Sensing, have entered into a connected injectable medicine collaboration.

The companies announced their partnership will focus on the development of smart connected monitoring and support solutions for patients who use injectable medicines, with the aim of improving administration so that efficacy and quality of the therapies can ultimately be improved.

Haselmeier’s subcutaneous drug delivery injection systems for self-administration will be combined with Common Sensing’s Gocap injector monitoring technology, creating a smart disposable injector pen platform, which is expected to be available in 2019.

“Haselmeier is excited about the collaboration with Common Sensing,” said Paul Jansen, Haselmeier senior advisor and board member. “Both companies have recognised how complementary their technologies were and how much this partnership will provide value for both Companies and patients. The joint relationship we have built will enable Haselmeier and Common Sensing to rapidly bring a unique connected pen solution on the market.”

“This partnership is a fantastic, market shaping opportunity to merge the leading edge, Haselmeier D-Flex injector with our Gocap connected health technology in a scalable, commercial platform,” added Kevin Schmid, common sensing chief operating officer.

“There is a high need to provide patients the means to better monitor the efficacy of their therapy and the injection experience is a crucial moment in a patient’s therapy. The collaboration of Haselmeier with Common Sensing is a smart and fast way to achieve our objective in improving patients’ lives,” commented Frédéric Gabriel, Haselmeier chief strategy officer.

The platform will be sold by Haselmeier and is expected to drive interest from both new and existing customers.